Vladan Milosavljevic, MD
Neurology · Lawrence, MANPI 1982691655
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,677 of the $128,548 with a category attached, or 71.3%. 56 manufacturers reported payments, led by AbbVie at 42.2% of the total. 2025 is the largest year on record at $31,937, 5.5 times the $5,849 reported in 2019. Among neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,529 payments — averaging $84.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$54K
- Supernus Pharmaceuticals, Inc.$51K
- Livanova USA, Inc.$5K
- Amneal Pharmaceuticals LLC$2K
- Novartis$2K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $14K from 50 others
Across 12 payments — averaging $5559.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$67K
What the payments were for
- Consulting fees$1,4611%
- Speaking & faculty fees$91,67771%
- Travel & lodging$9,2417%
- Food & beverage$25,74720%
- Education$4220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$45,668
- UBRELVY$39,425
- QULIPTA$24,531
- VNS Therapy$3,683
- KESIMPTA$390
- NOURIANZ$257
- MAYZENT$242
- ACTHAR$225
- PURIFIED CORTROPHIN GEL$204
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$148
- XEOMIN$145
- INBRIJA$145
- VRAYLAR$130
- VALTOCO$125
- AJOVY$119
- ZEPOSIA$114
- XCOPRI$110
- WAINUA$110
- VNS - Sentiva$103
- JORNAY PM$100
How this compares
$128,548 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 36 | $369,722 |
| AustedoDeutetrabenazine | 20 | $184,102 |
| IngrezzaValbenazine Tosylate | 12 | $99,157 |
| UbrelvyUbrogepant | 52 | $57,171 |
| GocovriAmantadine Hcl | 13 | $44,270 |
| Nurtec OdtRimegepant Sulfate | 32 | $39,427 |
| AptiomEslicarbazepine Acetate | 19 | $39,067 |
| FycompaPerampanel | 27 | $34,497 |
| BotoxOnabotulinumtoxina | 18 | $31,911 |
| BriviactBrivaracetam | 17 | $24,075 |
| RexultiBrexpiprazole | 17 | $23,801 |
| NourianzIstradefylline | 12 | $23,655 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 29 | $23,117 |
| NamzaricMemantine Hcl/Donepezil Hcl | 36 | $22,001 |
| DilantinPhenytoin Sodium Extended | 108 | $19,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $1,261 | $184,10220 claims |
| AbbVieUbrelvy, Botox, Namzaric | $54,275 | $111,083106 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $507 | $99,15712 claims |
| PfizerNurtec Odt, Dilantin | $328 | $58,629140 claims |
| MDD US Operations, LLCGocovri | $172 | $44,27013 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $479 | $39,06719 claims |
| Eisai Inc.Fycompa | $54 | $34,49727 claims |
| UCB, Inc.Briviact | $385 | $24,07517 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $36 | $23,80117 claims |
| Kyowa Kirin, Inc.Nourianz | $1,114 | $23,65512 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $461 | $16,20211 claims |
| SK Life Science, Inc.Xcopri | $294 | $15,09813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 761 neurology providers in Massachusetts.
Other neurology in Lawrence
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
- Pushpa NarayanaswamiBoston$420K
- Kenneth GorsonWellesley$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.